Literature DB >> 8347490

Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.

L Seymour1, W R Bezwoda.   

Abstract

The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX. Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable interest. IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical correlation with response to therapy. TGF beta expression was found in all patients prior to treatment and while all non-responders showed reduction of TGF beta following treatment, the alterations were variable amongst responders (including two patients with increased expression, one with no change, and one with decreased expression). It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are more complex than has been appreciated from the models. From the clinical point of view, it might be expected that treatment which enhances the expression of ER in tumours should have a positive effect on the response to TMX.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347490      PMCID: PMC1968584          DOI: 10.1038/bjc.1993.339

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression.

Authors:  S Ariad; L Seymour; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables.

Authors:  N J Barnard; P A Hall; N R Lemoine; N Kadar
Journal:  J Pathol       Date:  1987-08       Impact factor: 7.996

3.  Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells.

Authors:  G Sica; V Natoli; C Stella; S Del Bianco
Journal:  Cancer       Date:  1987-11-15       Impact factor: 6.860

4.  Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7).

Authors:  D P Edwards; D J Adams; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

5.  Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies.

Authors:  D J Adams; H Hajj; D P Edwards; R J Bjercke; W L McGuire
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

6.  Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.

Authors:  T J Powles; S Ashley; H T Ford; J C Gazet; A G Nash; A M Neville; R C Coombes
Journal:  Lancet       Date:  1984-06-23       Impact factor: 79.321

7.  Estrogen-induced 24K protein in MCF-7 breast cancer cells is localized in granules.

Authors:  D R Ciocca; D J Adams; D P Edwards; R J Bjercke; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

8.  Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

Authors:  C Knabbe; M E Lippman; L M Wakefield; K C Flanders; A Kasid; R Derynck; R B Dickson
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

9.  Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.

Authors:  H W van den Berg; W J Leahey; M Lynch; R Clarke; J Nelson
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

10.  Assessment of response to therapy in advanced breast cancer.

Authors:  J L Hayward; P P Carbone; J C Heusen; S Kumaoka; A Segaloff; R D Rubens
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more
  6 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Potential uses of interferon alpha 2 as adjuvant therapy in cancer.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

3.  Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).

Authors:  Gretchen Kimmick; Mark J Ratain; Don Berry; Susan Woolf; Larry Norton; Hyman B Muss
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

4.  S100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells.

Authors:  Stina Petersson; Anna Bylander; Maria Yhr; Charlotta Enerbäck
Journal:  BMC Cancer       Date:  2007-11-06       Impact factor: 4.430

5.  Influence of IFN-gamma and its receptors in human breast cancer.

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz A; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  BMC Cancer       Date:  2007-08-14       Impact factor: 4.430

6.  Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms.

Authors:  Qi Fang; Shuang Yao; Guanghua Luo; Xiaoying Zhang
Journal:  Oncotarget       Date:  2017-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.